Don’t Miss Variants: Upgrading From the Cited Variants Reference to the Mastermind API
In this blog, chief technology officer Steve Schwartz describes the limitations of the Mastermind Cited Variants Reference (CVR) that affect genomic analyses, and how the integration of Mastermind’s API can help surmount them.
Accelerating Rare Disease Diagnosis with Genomic Data
Genomenon CEO, Mike Klein, shares how Mastermind’s new Disease-Specific Curated Content is helping clinicians discover new treatment options for rare diseases.
Top Three Benefits of Locus-Specific Patient Databases for Rare Disease
In a recent webinar, Genomenon’s chief scientific officer Dr. Mark Kiel was joined by Dr. Gus Khursigara, VP of Medical Affairs and Clinical Strategy at Inozyme Pharma. This blog explores three key benefits of locus-specific patient databases (or Patient Landscapes), and how they are helping Inozyme better understand and target rare diseases.
Using Technology to Power Pharma and Clinical Genomics with Mike Klein
Genomenon CEO, Mike Klein met with Mike Maddox, host of ASK, to talk about Genomenon’s use of innovative technology to connect medical professionals with the scientific evidence they need to treat rare diseases and cancers.
Curating the Genome to Drive Drug Discovery
Genomenon Founder & Chief Science Officer, Dr. Mark Kiel, was a guest speaker at the 2019 Cutting Edge Drug Discovery & Development Symposium in Ann Arbor, Michigan on ‘Curating the Genome to Drive Drug Discovery’. Below are his slides and a transcript of his talk.